Johnson and Johnson seeks nod for vaccine trials on 12-17 age group

Pharma major’s single shot candidate was granted emergency use approval

Updated - August 20, 2021 08:50 pm IST

Published - August 20, 2021 06:43 pm IST - NEW DELHI

COVID-19 vaccine are seen in front of a displayed Johnson & Johnson logo in this illustration. File photo

COVID-19 vaccine are seen in front of a displayed Johnson & Johnson logo in this illustration. File photo

U.S. pharma major Johnson & Johnson (J&J) has applied for permission to conduct clinical trials of its single-shot COVID-19 vaccine on adolescents aged 12-17 years in India. The company has moved an application to the Central Drugs Standard Control Organisation (CDSCO) seeking approval.

J&J India spokesperson in a statement said: “We are committed to facilitating global equitable access to its COVID-19 vaccine and recognise the unmet needs of children. On August 17, 2021, we submitted an application to the CDSCO to conduct a study of the J & J COVID-19 vaccine in India in adolescents aged 12–17 years.

“To ultimately achieve herd immunity, it is imperative that COVID-19 vaccine clinical trials continue to move forward in this population, and we remain deeply committed to the critical work needed to make our COVID-19 vaccine equitably accessible for all age groups,” said the statement.

Previously in August, J&J’s single-dose COVID-19 vaccine had been granted emergency use approval (EUA) in India, and the Health Ministry has said it was in talks to get the vaccine available to the general public as soon as possible.

The five COVID vaccines granted EUA in India are Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V, Moderna and now Johnson & Johnson (J&J). Coronavirus vaccine developed by J&J has demonstrated 85% efficacy in staving off severe COVID-19 disease in its phase 3 trials.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.